Key result
Molecular markers predict treatment response and metastasis-free survival in 3 sarcoma cases.
Why the study?
Molecular markers in sarcomas have been primarily used for diagnosis but are increasingly applied for prognosis and prediction of therapy response.
Case Report (n=3)
Molecular markers are increasingly important for prognosis and predicting therapeutic response in sarcomas.
May support molecular profiling for sarcoma prognosis; hypothesis-generating from case reports, needing prospective validation.
The use of molecular markers in sarcomas has been primarily for diagnosis, but increasingly they are also used for prognosis and prediction of response to specific therapies. This article presents 3 case reports of sarcomas to illustrate molecular markers for prognosis/predictive purposes. The prototypical example is gastrointestinal stromal tumor, in which the response to imatinib mesylate therapy is predicted by analysis for KIT mutation. In synovial sarcomas, the type of fusion transcript correlates with the clinical course, with SST-SSX2 having better metastasis-free survival than SYT-SSX1. p53 Mutation is an important prognostic factor in multiple tumors, including Ewing sarcoma. Many studies are ongoing, and molecular analysis will become increasingly important in the treatment of sarcomas.
No takes yet. Share an insight, caveat, or question.
Holmes et al. (2014) conducted a case report in Sarcomas (n=3). Molecular markers (e.g., KIT mutation, fusion transcripts, p53 mutation) was evaluated. Molecular markers, including KIT mutation in GIST and fusion transcripts in synovial sarcomas, predict treatment response and metastasis-free survival in 3 case reports of sarcomas.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: